Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer

Daniela Marzioni, T. Lorenzi, R. Mazzucchelli, L. Capparuccia, M. Morroni, R. Fiorini, C. Bracalenti, A. Catalano, G. David, M. Castellucci, G. Muzzonigro, R. Montironi

Research output: Contribution to journalArticle

Abstract

Basic Fibroblast Growth Factor (bFGF) is a heparin-binding cationic protein involved in a variety of pathological conditions including angiogenesis and solid tumour growth. The basic Fibroblast Growth Factor Receptor (FGFR) family comprises at least 4 high affinity tyrosine kinase receptors that require syndecans for their function. Mounting evidence indicates that syndecans, that bind both bFGF and their FGFRs, will act as stimulators, whereas syndecans that only bind bFGF will act as inhibitors of signaling by sequestering the growth factor. Recent findings have highlighted the importance of syndecans in urological cancers. The aim of this study is to investigate the expression of bFGF, its receptors (R1 and R2) and syndecans (1-4) in invasive urothelial carcinoma and normal-looking urothelium by Western blotting, RT-PCR, and immunohistochemistry analyses. Interestingly, bFGF, FGFR1 and FGFR2 protein levels statistically increased in bladder cancer tissues. mRNA of FGFR1 and syndecans (1-4), showed a statistically significant increase while an mRNA increase in the other molecules analysed was not significant. bFGF, its receptors and syndecan immunostaining were mainly present in the urothelium both in normal-looking tissues and urothelial neoplastic cells. In conclusion, our data report that the bFGF, FGFR and syndecan expressions are altered in bladder tumours.

Original languageEnglish
Pages (from-to)627-638
Number of pages12
JournalInternational Journal of Immunopathology and Pharmacology
Volume22
Issue number3
Publication statusPublished - Jul 2009

Fingerprint

Syndecans
Fibroblast Growth Factor Receptors
Fibroblast Growth Factor 2
Urinary Bladder Neoplasms
Syndecan-4
Syndecan-1
Urothelium
Receptor, Fibroblast Growth Factor, Type 2
Receptor, Fibroblast Growth Factor, Type 1
Urologic Neoplasms
Messenger RNA
Receptor Protein-Tyrosine Kinases
Intercellular Signaling Peptides and Proteins
Western Blotting
Immunohistochemistry
Carcinoma
Polymerase Chain Reaction

Keywords

  • bFGF
  • Bladder
  • FGFRs
  • Immunohistochemistry
  • RT-PCR
  • Syndecans
  • Urothelial carcinoma
  • Western blotting

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Cite this

Marzioni, D., Lorenzi, T., Mazzucchelli, R., Capparuccia, L., Morroni, M., Fiorini, R., ... Montironi, R. (2009). Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. International Journal of Immunopathology and Pharmacology, 22(3), 627-638.

Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. / Marzioni, Daniela; Lorenzi, T.; Mazzucchelli, R.; Capparuccia, L.; Morroni, M.; Fiorini, R.; Bracalenti, C.; Catalano, A.; David, G.; Castellucci, M.; Muzzonigro, G.; Montironi, R.

In: International Journal of Immunopathology and Pharmacology, Vol. 22, No. 3, 07.2009, p. 627-638.

Research output: Contribution to journalArticle

Marzioni, D, Lorenzi, T, Mazzucchelli, R, Capparuccia, L, Morroni, M, Fiorini, R, Bracalenti, C, Catalano, A, David, G, Castellucci, M, Muzzonigro, G & Montironi, R 2009, 'Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer', International Journal of Immunopathology and Pharmacology, vol. 22, no. 3, pp. 627-638.
Marzioni D, Lorenzi T, Mazzucchelli R, Capparuccia L, Morroni M, Fiorini R et al. Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. International Journal of Immunopathology and Pharmacology. 2009 Jul;22(3):627-638.
Marzioni, Daniela ; Lorenzi, T. ; Mazzucchelli, R. ; Capparuccia, L. ; Morroni, M. ; Fiorini, R. ; Bracalenti, C. ; Catalano, A. ; David, G. ; Castellucci, M. ; Muzzonigro, G. ; Montironi, R. / Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. In: International Journal of Immunopathology and Pharmacology. 2009 ; Vol. 22, No. 3. pp. 627-638.
@article{2f28fd73dd4246bcb27d518ea3ac0af0,
title = "Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer",
abstract = "Basic Fibroblast Growth Factor (bFGF) is a heparin-binding cationic protein involved in a variety of pathological conditions including angiogenesis and solid tumour growth. The basic Fibroblast Growth Factor Receptor (FGFR) family comprises at least 4 high affinity tyrosine kinase receptors that require syndecans for their function. Mounting evidence indicates that syndecans, that bind both bFGF and their FGFRs, will act as stimulators, whereas syndecans that only bind bFGF will act as inhibitors of signaling by sequestering the growth factor. Recent findings have highlighted the importance of syndecans in urological cancers. The aim of this study is to investigate the expression of bFGF, its receptors (R1 and R2) and syndecans (1-4) in invasive urothelial carcinoma and normal-looking urothelium by Western blotting, RT-PCR, and immunohistochemistry analyses. Interestingly, bFGF, FGFR1 and FGFR2 protein levels statistically increased in bladder cancer tissues. mRNA of FGFR1 and syndecans (1-4), showed a statistically significant increase while an mRNA increase in the other molecules analysed was not significant. bFGF, its receptors and syndecan immunostaining were mainly present in the urothelium both in normal-looking tissues and urothelial neoplastic cells. In conclusion, our data report that the bFGF, FGFR and syndecan expressions are altered in bladder tumours.",
keywords = "bFGF, Bladder, FGFRs, Immunohistochemistry, RT-PCR, Syndecans, Urothelial carcinoma, Western blotting",
author = "Daniela Marzioni and T. Lorenzi and R. Mazzucchelli and L. Capparuccia and M. Morroni and R. Fiorini and C. Bracalenti and A. Catalano and G. David and M. Castellucci and G. Muzzonigro and R. Montironi",
year = "2009",
month = "7",
language = "English",
volume = "22",
pages = "627--638",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "3",

}

TY - JOUR

T1 - Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer

AU - Marzioni, Daniela

AU - Lorenzi, T.

AU - Mazzucchelli, R.

AU - Capparuccia, L.

AU - Morroni, M.

AU - Fiorini, R.

AU - Bracalenti, C.

AU - Catalano, A.

AU - David, G.

AU - Castellucci, M.

AU - Muzzonigro, G.

AU - Montironi, R.

PY - 2009/7

Y1 - 2009/7

N2 - Basic Fibroblast Growth Factor (bFGF) is a heparin-binding cationic protein involved in a variety of pathological conditions including angiogenesis and solid tumour growth. The basic Fibroblast Growth Factor Receptor (FGFR) family comprises at least 4 high affinity tyrosine kinase receptors that require syndecans for their function. Mounting evidence indicates that syndecans, that bind both bFGF and their FGFRs, will act as stimulators, whereas syndecans that only bind bFGF will act as inhibitors of signaling by sequestering the growth factor. Recent findings have highlighted the importance of syndecans in urological cancers. The aim of this study is to investigate the expression of bFGF, its receptors (R1 and R2) and syndecans (1-4) in invasive urothelial carcinoma and normal-looking urothelium by Western blotting, RT-PCR, and immunohistochemistry analyses. Interestingly, bFGF, FGFR1 and FGFR2 protein levels statistically increased in bladder cancer tissues. mRNA of FGFR1 and syndecans (1-4), showed a statistically significant increase while an mRNA increase in the other molecules analysed was not significant. bFGF, its receptors and syndecan immunostaining were mainly present in the urothelium both in normal-looking tissues and urothelial neoplastic cells. In conclusion, our data report that the bFGF, FGFR and syndecan expressions are altered in bladder tumours.

AB - Basic Fibroblast Growth Factor (bFGF) is a heparin-binding cationic protein involved in a variety of pathological conditions including angiogenesis and solid tumour growth. The basic Fibroblast Growth Factor Receptor (FGFR) family comprises at least 4 high affinity tyrosine kinase receptors that require syndecans for their function. Mounting evidence indicates that syndecans, that bind both bFGF and their FGFRs, will act as stimulators, whereas syndecans that only bind bFGF will act as inhibitors of signaling by sequestering the growth factor. Recent findings have highlighted the importance of syndecans in urological cancers. The aim of this study is to investigate the expression of bFGF, its receptors (R1 and R2) and syndecans (1-4) in invasive urothelial carcinoma and normal-looking urothelium by Western blotting, RT-PCR, and immunohistochemistry analyses. Interestingly, bFGF, FGFR1 and FGFR2 protein levels statistically increased in bladder cancer tissues. mRNA of FGFR1 and syndecans (1-4), showed a statistically significant increase while an mRNA increase in the other molecules analysed was not significant. bFGF, its receptors and syndecan immunostaining were mainly present in the urothelium both in normal-looking tissues and urothelial neoplastic cells. In conclusion, our data report that the bFGF, FGFR and syndecan expressions are altered in bladder tumours.

KW - bFGF

KW - Bladder

KW - FGFRs

KW - Immunohistochemistry

KW - RT-PCR

KW - Syndecans

KW - Urothelial carcinoma

KW - Western blotting

UR - http://www.scopus.com/inward/record.url?scp=70350551947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350551947&partnerID=8YFLogxK

M3 - Article

C2 - 19822079

AN - SCOPUS:70350551947

VL - 22

SP - 627

EP - 638

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 3

ER -